Nucleic Acids Research Advance Access originally published online on June 16, 2008
Nucleic Acids Research 2008 36(12):4158-4171; doi:10.1093/nar/gkn342
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nucleic Acids Research, 2008, Vol. 36, No. 12 4158-4171
© 2008 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Survey and Summary |
Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides
Department of Pharmacology, University of North Carolina, Chapel Hill, NC 27599, USA
*To whom correspondence should be addressed. Tel: +1 919 966 4383; Fax: +1 919 966 5640; Email: arjay{at}med.unc.edu
Received April 2, 2008. Revised May 9, 2008. Accepted May 12, 2008.
The potential use of antisense and siRNA oligonucleotides as therapeutic agents has elicited a great deal of interest. However, a major issue for oligonucleotide-based therapeutics involves effective intracellular delivery of the active molecules. In this Survey and Summary, we review recent reports on delivery strategies, including conjugates of oligonucleotides with various ligands, as well as use of nanocarrier approaches. These are discussed in the context of intracellular trafficking pathways and issues regarding in vivo biodistribution of molecules and nanoparticles. Molecular-sized chemical conjugates and supramolecular nanocarriers each display advantages and disadvantages in terms of effective and nontoxic delivery. Thus, choice of an optimal delivery modality will likely depend on the therapeutic context.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Olejniczak, P. Galka, and W. J. Krzyzosiak Sequence-non-specific effects of RNA interference triggers and microRNA regulators Nucleic Acids Res., October 20, 2009; (2009) gkp829v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Mitev, B. L. Mellbye, P. L. Iversen, and B. L. Geller Inhibition of Intracellular Growth of Salmonella enterica Serovar Typhimurium in Tissue Culture by Antisense Peptide-Phosphorodiamidate Morpholino Oligomer Antimicrob. Agents Chemother., September 1, 2009; 53(9): 3700 - 3704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Winkler, P. Martin-Killias, A. Pluckthun, and U. Zangemeister-Wittke EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins Mol. Cancer Ther., September 1, 2009; 8(9): 2674 - 2683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Marty, C. N. N'soukpoe-Kossi, D. M. Charbonneau, L. Kreplak, and H.-A. Tajmir-Riahi Structural characterization of cationic lipid-tRNA complexes Nucleic Acids Res., August 1, 2009; 37(15): 5197 - 5207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Romero-Lopez, R. Diaz-Gonzalez, A. Barroso-delJesus, and A. Berzal-Herranz Inhibition of hepatitis C virus replication and internal ribosome entry site-dependent translation by an RNA molecule J. Gen. Virol., July 1, 2009; 90(7): 1659 - 1669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Pabit, X. Qiu, J. S. Lamb, L. Li, S. P. Meisburger, and L. Pollack Both helix topology and counterion distribution contribute to the more effective charge screening in dsRNA compared with dsDNA Nucleic Acids Res., July 1, 2009; 37(12): 3887 - 3896. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Petri, M. Lindow, and S. Kauppinen MicroRNA Silencing in Primates: Towards Development of Novel Therapeutics Cancer Res., January 15, 2009; 69(2): 393 - 395. [Abstract] [Full Text] [PDF]
|
|